Drug therapy of cancer

Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592 Berrino F, De Angelis R, Sant M et al (2007) Survival for eight major cancers and all cancers combined for European adults diagnosed in 1955-99: results of the EUROCARE-4 study. Lancet Oncol 8:773–783 Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823 Mellor HR, Callaghan R (2008) Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 81:275–300 Kaye SB (2008) Reversal of drug resistance in ovarian cancer: where do we go from here? J Clin Oncol 26:2616–2618 Rosenberg B, Van Camp L, Grimley EB et al (1967) The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J Biol Chem 242:1347–1352 Rosenberg B, VanCamp L, Trosko JE et al (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222:385–386 Minotti G, Menna P, Salvatorelli E et al (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229 Heidelberger C, Ansfield FJ (1963) Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res 23:1226–1243 Elion GB (1989) The purine path to chemotherapy. Science 244:41–47 Plunkett W, Heinemann V, Estey E, Keating M (1990) Pharmacologically directed design of leukemia therapy. Haematol Blood Transfus 33:610–613 Carmichael J (1998) The role of gemcitabine in the treatment of other tumors. Br J Cancer 78(suppl 3):21–25 McLeod HL, Cassidy J, Powrie RH et al (2000) Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res 6:2677–2684 Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644 Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551 Petrelli F, Borgonovo K, Barni S (2010) Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin Pharmacother 11:1413–1432 De Bono JS, Oudard S, Ozguroglu M (2010) Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). J Clin Oncol 28:15s, abstract 4508 Gautschi O, Heighway J, Mack PC et al (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res 14:1639–1648 Skipper H, Schabel F, Wilcox W (1964) Experimental evaluation of potential anticancer agents. Cancer Chemother Rep 35:1–111 De Vita VT, Serpick A, Carbone PP (1970) Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73:881–895 Einhorn L (2002) Curing metastatic testicular cancer. Proc Nat Acad Sci USA 99:4592–4595 Bonadonna G, Brusamolino E, Valagussa P et al (1976) Combined chemotherapy as adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410 Bonadonna G, Moliterni A, Zambetti M et al (2005) 30 Years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217 Druker BJ, Lydon NB (2000) Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3–7 Druker B, Guilhot F, O’Brian S et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408–2417 Pollack VA, Savage DM, Baker DA et al (1999) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739–748 Baselga J, Averbuch SD (2000) ZD1839 ('Iressa') as an anticancer agent. Drugs 60(suppl 1):33–40 Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521–529 Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124 Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134 Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338 Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–90 Hamilton M, Wolf JL, Rusk J et al (2006) Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 12:2166–2171 Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–7 Grillo-López AJ, White CA, Varns C et al (1999) Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 5(Suppl 14):66–73 Goldenberg MM (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 2:309–318 Garnock-Jones KP, Keating GM, Scott LJ (2010) Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 70:215–239 Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175:409–416 Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400 Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676 Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1742 Soulières D, Greer W, Magliocco AM et al (2010) KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol 17(Suppl 1):S31–40 Rowinsky EK, Schwartz GH, Gollob JA (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003–15 Wolchok JD, Neyns B, Linette G (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155–64 O'Day FS, Hodi DF, McDermott RW et al (2010) A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol 28:18s Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819 Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z et al (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973–977 Sparks CA, Guertin DA (2010) Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29:3733–3744 Houghton PJ (2010) Everolimus. Clin Cancer Res 16:1368–1372 Yin L, Velazquez OC, Liu ZJ (2010) Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol 80:690–701 Gualberto A, Pollak M (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28:3009–21 Murnane JP (2010) Telomere loss as a mechanism for chromosome instability in human cancer. Cancer Res 70:4255–9 Shay JW, Keith WN (2008) Targeting telomerase for cancer therapeutics. Br J Cancer 98:677–83 Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153–66 Nahi H, Selivanova G, Lehmann S et al (2008) Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br J Haematol 141:445–453 Lambert JM, Gorzov P, Veprintsev DB et al (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15:376–388 Herrstedt J (2008) Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 5:32–43 Hesketh PJ (2001) Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer 9:350–354 Murgo AJ, Kummar S, Rubinstein L et al (2008) Designing phase 0 cancer clinical trials. Clin Cancer Res 14:3675–3682 Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197:461–463 Glas AM, Floore A, Delahaye JMJ et al (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7:278 Dewit O, Starkel P, Roblin X (2010) Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur J Clin Invest 40:1037–1047 Desta Z, Ward BA, Soukhova NV, Flockahart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A4 and CYP2D6. J Pharmacol Exp Ther 310:1062–1075 Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60–62 Richardson MA, Sanders T, Palmer JL et al (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514